Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(4.28)
# 1,426
Out of 4,673 analysts
119
Total ratings
40.4%
Success rate
15.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IVA Inventiva | Initiated Coverage: Buy | n/a | $4.68 | - | 1 | Jul 17, 2026 | |
| SLN Silence Therapeutics | Initiated Coverage: Buy | n/a | $13.27 | - | 1 | Jun 24, 2026 | |
| GPCR Structure Therapeutics | Maintained: Buy | $101 | $49.09 | +105.74% | 10 | Jun 7, 2026 | |
| STTK Shattuck Labs | Initiated Coverage: Buy | n/a | $7.53 | - | 1 | Apr 27, 2026 | |
| ZLDPF Zealand Pharma A/S | Downgraded: Hold | n/a | $50.51 | - | 4 | Mar 6, 2026 | |
| MANE Veradermics | Initiated Coverage: Buy | n/a | $102.82 | - | 1 | Mar 1, 2026 | |
| TVTX Travere Therapeutics | Reiterated: Buy | n/a | $65.71 | - | 7 | Feb 20, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | n/a | $15.76 | - | 9 | Dec 4, 2025 | |
| EVMN Evommune | Initiated Coverage: Buy | n/a | $14.02 | - | 1 | Dec 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Upgraded: Buy | n/a | $516.74 | - | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.41 | - | 2 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $14.20 | - | 6 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.5015 | - | 10 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $19.83 | n/a | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.89 | n/a | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $36.30 | n/a | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $87.11 | n/a | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $54.27 | n/a | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.03 | n/a | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $2.8 | $2.31 | n/a | 10 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.67 | n/a | 2 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $3.5 | $1.76 | n/a | 3 | Jan 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 → $23 | $4.05 | n/a | 8 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 → $62 | $8.87 | n/a | 8 | Oct 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $44 | $25.08 | n/a | 8 | Sep 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 | $1.52 | n/a | 8 | Aug 5, 2021 |
Inventiva
Jul 17, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $4.68
Upside: -
Silence Therapeutics
Jun 24, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $13.27
Upside: -
Structure Therapeutics
Jun 7, 2026
Maintained: Buy
Price Target: $101
Current: $49.09
Upside: +105.74%
Shattuck Labs
Apr 27, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $7.53
Upside: -
Zealand Pharma A/S
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $50.51
Upside: -
Veradermics
Mar 1, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $102.82
Upside: -
Travere Therapeutics
Feb 20, 2026
Reiterated: Buy
Price Target: n/a
Current: $65.71
Upside: -
MoonLake Immunotherapeutics
Dec 4, 2025
Maintained: Buy
Price Target: n/a
Current: $15.76
Upside: -
Evommune
Dec 1, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $14.02
Upside: -
Madrigal Pharmaceuticals
Nov 4, 2025
Upgraded: Buy
Price Target: n/a
Current: $516.74
Upside: -
Oct 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $6.41
Upside: -
Sep 26, 2025
Reiterated: Buy
Price Target: n/a
Current: $14.20
Upside: -
Sep 15, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.5015
Upside: -
Aug 15, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $19.83
Upside: n/a
Jul 7, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.89
Upside: n/a
Jun 18, 2025
Reiterated: Buy
Price Target: n/a
Current: $36.30
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $87.11
Upside: n/a
Mar 3, 2025
Reiterated: Buy
Price Target: n/a
Current: $54.27
Upside: n/a
Jan 21, 2025
Downgraded: Hold
Price Target: n/a
Current: $11.03
Upside: n/a
Aug 11, 2023
Maintained: Buy
Price Target: $14 → $2.8
Current: $2.31
Upside: n/a
Mar 17, 2023
Rated: Hold
Price Target: n/a
Current: $6.67
Upside: n/a
Jan 10, 2023
Maintained: Buy
Price Target: $5 → $3.5
Current: $1.76
Upside: n/a
Sep 12, 2022
Maintained: Buy
Price Target: $27 → $23
Current: $4.05
Upside: n/a
Oct 18, 2021
Maintained: Buy
Price Target: $58 → $62
Current: $8.87
Upside: n/a
Sep 21, 2021
Maintained: Buy
Price Target: $44
Current: $25.08
Upside: n/a
Aug 5, 2021
Maintained: Buy
Price Target: $22
Current: $1.52
Upside: n/a